cagrisema phase 3 results 2025 semaglutide cagrilintide obesity Updates in Medicine | 🔬 REDEFINE 2: in T2D + Original article link in bio 👥 3a RCT in 1206 adults with T2D (BMI ≥27, HbA1c 7–10%) 💉 cagrisema cagrilintide semaglutide phase 3

Long Arginine 3-IGF-1 Modified Single-Letter Sequence: MFPAMPLLSLFVNIGF-1 core sequence (83 amino acids total) IUPAC Condensed Amino Acid Sequence: MFPAMPLLSLFVNGPRTLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA Molecular Weight: 9117.6 g/mol CAS Number: 143045-27-6 PubChem CID: 16130518 Further Reference: PubChem Link Stability: Store lyophilised peptide at 20 C

This is part of the design to make sure each dose you take is accurate and complete

Peptide Blend Vials (12 mg each): 8 weeks (~11.2 mL total): 4 vials 12 weeks (~16.8 mL total): 6 vials 16 weeks (~22.4 mL total): 8 vials Insulin Syringes (U100): Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution

While the FDAs action narrows the scope of disputed risks tied to GLP-1 medications, it does not address the gastrointestinal and vision-related injury claims that remain central to the ongoing litigation

Skin reactions can range from mild, localised rashes to more significant hypersensitivity responses , though severe reactions are rare

Unlike the occasional craving, food noise feels like constant, intrusive thoughts about eating whether youre physically hungry or not